This study calculated an average annual per-patient treatment cost ranging from a minimum of € 1,500 to a maximum of € 3,913, depending on the severity of the disease. The actual annual cost of COPD in Italy was assessed for the first time by a Real Word Data (RWD) observational study conducted in a large region of northeast Italy (Triveneto), between 19. ![]() These aspects contribute to the overall disease severity, reduce health-related quality of life and make COPD one of the chronic progressive diseases with the highest socio-economic cost. The natural history of the disease is characterized by exacerbations, progressive decline in pulmonary function and further concomitant chronic diseases such as cardiovascular diseases, osteoporosis, skeletal muscle dysfunction, metabolic syndrome, depression/anxiety and lung cancer. The most significant risk factor for COPD is long-term cigarette smoking, but also other environmental exposures such as biomass fuel exposure and air pollution may play a potential role. According to WHO estimates, COPD is projected to become the third leading cause of death worldwide for all age group in 2030. In coming decades, Chronic Obstructive Pulmonary Disease (COPD) is expected to globally increase because of the continued exposure to COPD risk factors and aging of the population. Clinicians should consider the potential benefits of finding less expensive regimens while maintaining adequate efficacy in the prescriptive decision making process of COPD patients. ConclusionĪ pre-fixed ICS/LAMA/LABA SITT is cost-saving, compared to the different currently used extemporaneous MITTs. The cheapest pre-established SITT contained the fluticasone furoate/umeclidinium/vilanterol (FF/UMEC/VI) combination. The expanded use of a pre-established ICS/LAMA/LABA SITT was associated to a significant economic saving, ranging from a minimum of -€ 1,108,814 (SITT use: 30%) to a maximum of -€ 3,658,950 (SITT use: 100%). This association of medicaments was paradoxically also the one associated to the highest expense value. Our analysis showed that the extemporaneous MITT with the highest prevalence on the reference market was the inhaled corticosteroids/long-acting β 2-agonists (ICS/LABA) combination plus a long-acting muscarinic antagonists (LAMA). Drug costs were based on prices published on the Official Gazette and therapy durations were based on prescribing information over the year 2019 (IQVIA™ prescription dataset). MethodsĪ budget impact model was developed hypothesizing the progressive replacement of the different MITTs on the reference market (Scenario A) with the pre-established SITTs, assuming a degree of penetration of 30%, 50% and 100% (Scenario B). ![]() This study aimed to evaluate the potential saving deriving from the implementation in the prescription of the two currently available single-inhaler triple therapies (SITTs) versus the currently used multiple-inhaler triple therapies (MITTs) in an eligible COPD population residing in the Apulia Region. At the same time, severe COPD treatment, that often require a combination of medicaments, represents a substantial economic burden for the National Health Systems (NHS). The most impacting direct costs associated to COPD for the National Health Systems (NHS) are those related to accesses to the emergency room and hospital admissions, due to the onset of one or more COPD exacerbations.
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |